Renalytix (RENX) Competitors GBX 9.95 +0.45 (+4.74%) (As of 12/20/2024 09:57 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesInsider Trades RENX vs. KOO, COG, INHC, IQAI, FDBK, DVRG, TRLS, SENS, EMIS, and CRWShould you be buying Renalytix stock or one of its competitors? The main competitors of Renalytix include Kooth (KOO), Cambridge Cognition (COG), Induction Healthcare Group (INHC), IQ-AI (IQAI), Feedback (FDBK), DeepVerge (DVRG), Trellus Health (TRLS), Sensyne Health (SENS), EMIS Group (EMIS), and Craneware (CRW). These companies are all part of the "health information services" industry. Renalytix vs. Kooth Cambridge Cognition Induction Healthcare Group IQ-AI Feedback DeepVerge Trellus Health Sensyne Health EMIS Group Craneware Kooth (LON:KOO) and Renalytix (LON:RENX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, valuation, earnings, community ranking, profitability, dividends, analyst recommendations, institutional ownership and media sentiment. Do insiders & institutionals believe in KOO or RENX? 65.0% of Kooth shares are owned by institutional investors. Comparatively, 28.4% of Renalytix shares are owned by institutional investors. 17.3% of Kooth shares are owned by company insiders. Comparatively, 35.7% of Renalytix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to KOO or RENX? In the previous week, Renalytix had 2 more articles in the media than Kooth. MarketBeat recorded 2 mentions for Renalytix and 0 mentions for Kooth. Renalytix's average media sentiment score of 0.49 beat Kooth's score of 0.35 indicating that Renalytix is being referred to more favorably in the news media. Company Overall Sentiment Kooth Neutral Renalytix Neutral Which has stronger earnings & valuation, KOO or RENX? Kooth has higher revenue and earnings than Renalytix. Renalytix is trading at a lower price-to-earnings ratio than Kooth, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKooth£54.17M1.10£4.28M£0.121,362.08Renalytix£2.29M7.21-£33.46M-£0.24-41.46 Do analysts rate KOO or RENX? Kooth currently has a consensus price target of GBX 585, suggesting a potential upside of 257.91%. Given Kooth's stronger consensus rating and higher possible upside, equities analysts clearly believe Kooth is more favorable than Renalytix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kooth 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Renalytix 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more volatility & risk, KOO or RENX? Kooth has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500. Comparatively, Renalytix has a beta of 2.1, indicating that its stock price is 110% more volatile than the S&P 500. Is KOO or RENX more profitable? Kooth has a net margin of 7.89% compared to Renalytix's net margin of 0.00%. Kooth's return on equity of 23.83% beat Renalytix's return on equity.Company Net Margins Return on Equity Return on Assets Kooth7.89% 23.83% 10.12% Renalytix N/A -1,073.18%-93.54% Does the MarketBeat Community believe in KOO or RENX? Renalytix received 13 more outperform votes than Kooth when rated by MarketBeat users. However, 90.91% of users gave Kooth an outperform vote while only 74.19% of users gave Renalytix an outperform vote. CompanyUnderperformOutperformKoothOutperform Votes1090.91% Underperform Votes19.09%RenalytixOutperform Votes2374.19% Underperform Votes825.81% SummaryKooth beats Renalytix on 12 of the 18 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowAll of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Renalytix News Delivered to You Automatically Sign up to receive the latest news and ratings for RENX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RENX vs. The Competition Export to ExcelMetricRenalytixHealth Information Services IndustryMedical SectorLON ExchangeMarket Cap£16.51M£196.58M£5.14B£1.85BDividend YieldN/A6.94%5.09%10.60%P/E Ratio-41.46540.3889.821,786.40Price / Sales7.21285.021,116.21377,495.10Price / Cash1.8447.1442.8928.01Price / Book-1.995.074.782.91Net Income-£33.46M-£8.11M£120.23M£155.90M7 Day Performance8.74%-0.95%-1.92%-1.91%1 Month Performance32.67%6.21%11.49%17.62%1 Year Performance-28.93%11.55%30.57%29.01% Renalytix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RENXRenalytixN/AGBX 9.95+4.7%N/A-28.9%£16.51M£2.29M-41.46102News CoverageKOOKooth2.2888 of 5 starsGBX 169.50+0.9%GBX 585+245.1%-45.5%£61.83M£54.17M1,416.67478Positive NewsCOGCambridge CognitionN/AGBX 30.50-1.6%N/A-37.9%£12.79M£13.08M-751.2580News CoverageGap UpHigh Trading VolumeINHCInduction Healthcare GroupN/AGBX 9-5.3%N/A-61.5%£8.45M£13.65M-316.6774Gap DownIQAIIQ-AIN/AGBX 1.47-2.0%N/A-63.0%£3.26M£538,190.00-13.676Gap UpFDBKFeedbackN/AGBX 17.35-4.9%N/A-75.9%£2.31M£1.18M-71.0024DVRGDeepVergeN/AGBX 0.15flatN/AN/A£1.14M£12.41M-15.0073TRLSTrellus HealthN/AGBX 0.58-3.3%N/A-82.9%£937,000.00£35,000.00-20.0031Gap DownHigh Trading VolumeSENSSensyne HealthN/AGBX 0.35-33.3%N/AN/A£583,000.00£7.81M-0.0270Gap DownEMISEMIS GroupN/AN/AN/AN/A£1.23B£176.86M4,085.111,560CRWCraneware1.4374 of 5 starsGBX 2,300-1.7%GBX 2,700+17.4%+22.9%£812.82M£189.27M9,192.31734 Related Companies and Tools Related Companies Kooth Competitors Cambridge Cognition Competitors Induction Healthcare Group Competitors IQ-AI Competitors Feedback Competitors DeepVerge Competitors Trellus Health Competitors Sensyne Health Competitors EMIS Group Competitors Craneware Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:RENX) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Renalytix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RENX Stock Alerts